A subject of the invention is a compound 3-dodecylsulfanyl-butyric acid for use as a drug, especially for use in the treatment and prevention of the development of insulin resistance. The invention also relates to a pharmaceutical composition containing 3-dodecylsulfanyl-butyric acid as an active ingredient, and to the use of 3-dodecylsulfanyl-butyric acid for the manufacture of a drug for the prevention of insulin resistance.

Patent was granted in Poland. Nencki Institute is the co-owner of the applicable rights with University of Warmia and Mazury. Institute is the leader of patent protection and commercialization related activities.

For more information contact Technology Transfer Office.